Evidence map›Paper›PMID 36952300›Full record

ReviewCanadian Urological Association journal = Journal de l'Association des urologues du Canada2023

The impact of tranexamic acid on perioperative outcomes in urological surgeries A systematic review and meta-analysis.

John Kim, Abdullah Alrumaih, Conor Donnelly, Michael Uy, Jen Hoogenes, Edward D Matsumoto

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05947435 (The Effect of Use of Tranexamic Acid in Percutaneous Nephrolithotomy on Blood Loss and Surgical Visual Clarity), which is not on this map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05947435 nacompletednot on this map

The Effect of Use of Tranexamic Acid in Percutaneous Nephrolithotomy on Blood Loss and Surgical Visual Clarity

TypeinterventionalSponsorHaseki Training and Research HospitalRan2022 to 2023Enrolled75ConditionsPercutaneous Nephrolithotomy, Intraoperative Use of Tranexamic AcidArmsTranexamic acid
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Tranexamic acid for percutaneous nephrolithotomy.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John KimDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Abdullah AlrumaihDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Conor DonnellyMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Michael UyDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Jen HoogenesSt. Joseph's Healthcare Hamilton, Division of Urology, Hamilton, ON, Canada.
Edward D MatsumotoDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTranexamic acid (TXA) is an antifibrinolytic agent widely used in surgery to decrease bleeding and reduce the need for blood product transfusion. The role of TXA in urology is not well-summarized. We conducted a systematic review of studies reporting outcomes of TXA use in urological surgery.

methodsA comprehensive search was conducted from the following databases: PubMed, Embase, Cochrane Library, and Web of Science. Two reviewers performed title and abstract screening, full-text review, and data collection. Primary outcomes included estimated blood loss (EBL), decrease in hemoglobin, decrease in hematocrit, and blood transfusion rates. Secondary outcomes included TXA administration characteristics, length of stay, operative time, and postoperative thromboembolic events.

resultsA total of 26 studies consisting of 3261 patients were included in the final analysis. These included 11 studies on percutaneous nephrolithotomy, 10 on transurethral resection of prostate, three on prostatectomy, and one on cystectomy. EBL, transfusion rate, hemoglobin drop, operative time, and length of stay were significantly improved with TXA administration. In addition, the use of TXA was not associated with an increased risk of venous thromboembolism (VTE ). The route, dosage, and timing of TXA administration varied considerably between included studies.

conclusionsTXA use may improve blood loss, transfusion rates, and perioperative parameters in urological procedures. In addition, there is no increased risk of VTE associated with TXA use in urological surgery; however, there is still a need to determine the most effective TXA administration route and dose. This review provides evidence-based data for decision-making in urological surgery.

Identifiers

PMID36952300
PMCPMC10263287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.